Aytu BioScience, a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, agreed to merge with Neos Therapeutics, a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, in a $45m deal. “This is a truly transformative transaction, elevating the newly combined company to a $100 million revenue, leading specialty pharmaceutical company positioned for what we expect to be an accelerated path to profitability, continued revenue growth and further business diversification. The combination of Neos with the Aytu business further increases our footprint in an attractive pediatric medicine market, following our acquisition of the Cerecor pediatric Rx assets late last year. This transaction is an excellent strategic fit with our market expansion plans and we believe creates strong stockholder value,” Josh Disbrow, Aytu BioScience Chief Executive Officer.